The pathological mechanisms, mediators, and therapeutic strategies for cancer-related fatigue
Acta Pharmaceutica Sinica B · 2026-11
DOI: 10.1016/j.apsb.2026.11.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Hui Xu und 10 weiteren Autor:innen. Die Arbeit nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Cancer-related fatigue (CRF) is one of the most prevalent and distressing symptoms in patients with cancer, severely impairing patients’ quality of life and undermining treatment adherence. Notably, CRF occurs throughout tumor progression and post-treatment phases, often independently of the tumor’s status, highlighting its complex and multifactorial nature. Mechanistically, the pathogenesis of CRF arises from the interplay between central nervous system dysregulation and peripheral metabolic alterations, including skeletal muscle dysfunction, adipose tissue remodeling, and hepatic metabolic reprogramming. Emerging evidence further indicates that CRF may be driven by a diverse array of bioactive mediators in tumor progression and treatment, including macromolecules, water-soluble small molecules, lipid-soluble small molecules, extracellular vesicles (EVs), and other mediators. In this review, we comprehensively summarize these key regulatory mediators and further integrate current therapeutic strategies targeting CRF. In addition, we outline commonly used clinical assessment tools and evaluation criteria in animal models, providing a translational perspective. Collectively, this review proposes a conceptual framework centered on the “tumor – mediator – host” axis, offering an understanding of CRF pathogenesis and a foundation for the development of more effective diagnostic and therapeutic approaches.
Förderung
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
Zitieren
APA
Xu, H., Wang, H., Ru, N., Li, Y., Liang, L., Yuan, C., Xu, W., Zheng, X., Liu, J., Wu, Y., & He, R. (2026). The pathological mechanisms, mediators, and therapeutic strategies for cancer-related fatigue. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.11.016
Vancouver
Xu H, Wang H, Ru N, Li Y, Liang L, Yuan C, et al. The pathological mechanisms, mediators, and therapeutic strategies for cancer-related fatigue. Acta Pharmaceutica Sinica B. 2026. doi:10.1016/j.apsb.2026.11.016
BibTeX
@article{Xu2026,
author = {Xu, Hui and Wang, Hua-Jun and Ru, Nan and Li, Yi-Fang and Liang, Lei and Yuan, Cheng and Xu, Wen-Dong and Zheng, Xiao-Fei and Liu, Ju-Yan and Wu, Yan-Ping and He, Rong-Rong},
title = {The pathological mechanisms, mediators, and therapeutic strategies for cancer-related fatigue},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
doi = {10.1016/j.apsb.2026.11.016}
}
EUVIMED